Capricor Therapeutics Inc Revenue per Employee (CAPR), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Capricor Therapeutics inc   (NASDAQ: CAPR)
 

Capricor Therapeutics Inc 's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales



Within the Healthcare sector Capricor Therapeutics inc achieved the highest revenue per employee. While revenue per employee remained unchanged compared to the previous quarter at no. .Capricor Therapeutics Inc has 231 employees.


What is Sales per Employee Ratio?






Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CAPR Revenue per Employee (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Revenue Change - - - - -
Sales per Employee (TTM) $ - - 48,184 57,975 75,167
CAPR's Total Ranking # # # # #
Seq. Revenue Change - - - - -

CAPR Company Profile >> Back to CAPR Efficiency Comparisons >> Compare CAPR Sales per Employee to its Competitors

Revenue per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #

Revenue per Employee Statistics
High Average Low
$ 117,542 $ 28,749 $ 716
(Jun 30 2024)   (Mar 31 2021)



Financial Statements
Capricor Therapeutics Inc 's Revenue MRQ $ 0 Millions Visit CAPR's Income Statement
Capricor Therapeutics Inc 's Revenues TTM $ 0 Millions Visit CAPR's aggregate revenue growth
What are CAPR's Sales? Visit CAPR's Sales by Segment


  News about Capricor Therapeutics inc Revenue per employee

Capricor Therapeutics Advances Duchenne Muscular Dystrophy Program With Positive FDA Inspection Outcome

Capricor Therapeutics, a biotechnology company focused on developing innovative cell and exosome-based therapeutics for rare diseases, has announced significant regulatory progress for its Duchenne Muscular Dystrophy (DMD) program. The company reported the successful completion of a Pre-License Inspection (PLI) of its manufacturing facility located in San Diego by the U.S. Food and Drug Administration (FDA) for its lead therapeutic candidate, Deramiocel.Deramiocel is currently undergoing review for approval through a Biologics License Application (BLA), aimed at providing a promising treatment option for patients suffering from DMD, a progressive muscular disorder that primarily affects young males and leads to severe muscle degeneration and weakness.



Other Ratios
Capricor Therapeutics Inc 's Income per Employee
Employees in Major Pharmaceutical Preparations
Major Pharmaceutical Preparations Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
CAPR's Revenue per Employee versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for CAPR's Competitors
Revenue per Employee for CAPR's Suppliers
Revenue per Employee for CAPR's Customers

You may also want to know
CAPR's Sales Growth Rates CAPR's Pe Price to earnings ratio CAPR's Receivables Turnover Ratio CAPR's Stock Quote
CAPR's Net Income Growth Rates CAPR's Ps Price to Sales ratio CAPR's Sales per Employee CAPR's Asset Turnover Ratio
CAPR's Net Margin CAPR's Pb Price to Book ratio CAPR's Financial Strength Ratios CAPR's Dividend Payout Ratio
Date modified: 2026-08-30T14:47:28+00:00




Companies with similar Revenue per Employee for 12 months ending Mar 31 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Mar 31 2026Number of Employees Mar 31 2026




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.